Clinical trial of icotinib tablets in the treatment of stage ⅢA-N2 non-small cell lung cancer
10.13699/j.cnki.1001-6821.2018.09.008
- VernacularTitle:埃克替尼片治疗ⅢA-N2期非小细胞肺癌的临床研究
- Author:
Jian-Guo WANG
1
;
Shu-Xian WANG
;
Meng-Yuan TIAN
;
Yan WANG
;
Yu-Xiang RUAN
;
Sheng-Nan HUANG
Author Information
1. 河北大学附属医院检验科
- Keywords:
icotinib tablet;
stage ⅢA-N2 non-small cell lung cancer;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(9):1035-1038
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of icotinib tablets in the treatment of stage Ⅲ A-N2 non-small cell lung cancer (NSCLC).Methods A total of 56 patients with stage ⅢA-N2 NSCLC were randomly divided into control group and treatment group with 28 cases per group.The control group was treated with 60-75 mg · m-2 docetaxel,once a week,intravenous drip,or 500 mg · m pemetrexed,once every 3 weeks,intravenous drip,discontinuation of treatment when the disease progresses or adverse drug reactions cannot be tolerated.The treatment group was treated with icotinib tablets 125 mg,tid,orally,discontinuation of treatment when the disease progresses or adverse drug reactions cannot be tolerated.The clinical efficacy,peripheral blood dendritic cell subsets,and adverse drug reactions were compared between two groups.Results After treatment,the objective remission rates of the treatment group and the control group were 89.29％ (25 cases/28 cases) and 71.43％ (22 cases/28 cases),the difference was statistically significant (P ＜ 0.05).After treatment,the number of dendritic cells (DC) in the treatment group and the control group were (15.44 ± 2.08) and (12.83 ± 1.71) × 106/L,the ratio of dendritic cells to mononuclear cells (DC/PBMC) were (0.62 ± 0.08) ％ and (0.57 ± 0.07) ％,the differences were statistically significant (P ＜ 0.05).The adverse drug reactions of two groups were rashes,diarrhea and mild liver dysfunction.The total incidences of adverse drug reactions in the treatment group and the control group were 46.43％ and 42.86％ without significant difference (P ＞ 0.05).Conclusion The clinical efficacy of icotinib tablets in the treatment of stage ⅢA-N2 NSCLC was exact,and it did not increase the incidence of adverse drug reactions.
